Treatment of Acute Myelogenous Leukemia

Alexander A. Morley, Habib Ghaddar, Paolo Anderlini, Elihu Estey, Barry Meisenberg, Robert Zittoun, Franco Mandelli, Stefan Suciu

Research output: Contribution to journalLetterpeer-review

1 Scopus citations


To the Editor: The report by Zittoun et al. (Jan. 26 issue)1 on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.

Original languageEnglish (US)
Pages (from-to)1717-1719
Number of pages3
JournalNew England Journal of Medicine
Issue number25
StatePublished - Jun 22 1995
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Treatment of Acute Myelogenous Leukemia'. Together they form a unique fingerprint.

Cite this